Financial Analysis: Brainsway (NASDAQ:BWAY) versus Ingen Technologies (OTCMKTS:IGNT)

Ingen Technologies (OTCMKTS:IGNTGet Free Report) and Brainsway (NASDAQ:BWAYGet Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Analyst Ratings

This is a summary of current ratings for Ingen Technologies and Brainsway, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ingen Technologies 0 0 0 0 0.00
Brainsway 0 1 2 0 2.67

Brainsway has a consensus price target of $20.50, indicating a potential upside of 18.70%. Given Brainsway’s stronger consensus rating and higher probable upside, analysts plainly believe Brainsway is more favorable than Ingen Technologies.

Profitability

This table compares Ingen Technologies and Brainsway’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ingen Technologies N/A N/A N/A
Brainsway 12.73% 9.46% 5.96%

Risk and Volatility

Ingen Technologies has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Brainsway has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.

Valuation and Earnings

This table compares Ingen Technologies and Brainsway”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ingen Technologies N/A N/A N/A N/A N/A
Brainsway $41.02 million 8.24 $2.92 million $0.30 57.57

Brainsway has higher revenue and earnings than Ingen Technologies.

Insider & Institutional Ownership

30.1% of Brainsway shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Brainsway beats Ingen Technologies on 10 of the 10 factors compared between the two stocks.

About Ingen Technologies

(Get Free Report)

Ingen Technologies, Inc. engages in the research and development of home healthcare products for the respiratory industry in United States. It offers oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademark names for patients suffering with chronic obstructive pulmonary disease. The company was founded in 1999 and is based in Riverside, California.

About Brainsway

(Get Free Report)

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Ingen Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingen Technologies and related companies with MarketBeat.com's FREE daily email newsletter.